Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma – Analyses From the German Clinical RCC-Registry

Goebell, Peter J.; Staehler, Michael; Müller, Lothar; Nusch, Arnd; Scheffler, Michael; Sauer, Annette; Verschuer, Ulla Von; Tech, Susanne; Kruggel, Lisa; Jänicke, Martina; Marschner, Norbert

doi:10.1016/j.clgc.2018.06.006

Cited by 22 publications

(40 citation statements)

References 55 publications

(91 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast to the patients with nccmRCC, those with ccmRCC had a median OS of 22.3 months in the IMDC study . This is similar to our recently published data on treatment reality and effectiveness of treatment in patients with ccmRCC from the RCC‐Registry, which have shown a median OS of 20.4 and 26.2 months for the ccmRCC population and the potentially trial‐eligible subgroup, respectively …”

Section: Discussionsupporting

confidence: 86%

“…Here, we present first prospective data on treatment and survival of patients with pmRCC in routine practice. Our data reveal that patients with pmRCC have been treated with the same strategies used for patients with ccmRCC . Overall, the most frequently applied first‐line treatments between 2007 and 2017 were sunitinib, temsirolimus and, since 2011–2013, also pazopanib.…”

Section: Discussionmentioning

confidence: 80%

“…Our data reveal that patients with pmRCC have been treated with the same strategies used for patients with ccmRCC. 18 Overall, the most frequently applied first-line treatments between 2007 and 2017 were sunitinib, temsirolimus and, since 2011-2013, also pazopanib. Sunitinib was the targeted agent of choice in 2007-2010, which is similar to the results reported from a retrospective study of the International mRCC Database Consortium (IMDC) that has aimed to apply the IMDC prognostic model in patients with nccmRCC (n = 252; of these, 60% with pmRCC).…”

Section: Discussionmentioning

confidence: 99%

“…At the time of this analysis, 122 sites (clinics and outpatient centres) located across Germany actively participated and more than 1,500 patients have been enrolled to date. Further details on the methodology of the RCC‐Registry have been previously described elsewhere …”

Section: Methodsmentioning

confidence: 99%

“…Further details on the methodology of the RCC-Registry have been previously described elsewhere. 18,19…”

Section: Data Sourcementioning

confidence: 99%

See 4 more Smart Citations

Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC‐Registry

Staehler

Goebell

Müller³

et al. 2019

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Non‐clear cell renal cell carcinoma is a very rare malignancy that includes several histological subtypes. Each subtype may need to be addressed separately regarding prognosis and treatment; however, no Phase III clinical trial data exist. Thus, treatment recommendations for patients with non‐clear cell metastatic RCC (mRCC) remain unclear. We present first prospective data on choice of first‐ and second‐line treatment in routine practice and outcome of patients with papillary mRCC. From the prospective German clinical cohort study (RCC‐Registry), 99 patients with papillary mRCC treated with systemic first‐line therapy between December 2007 and May 2017 were included. Prospectively enrolled patients who had started first‐line treatment until May 15, 2016, were included into the outcome analyses (n = 82). Treatment was similar to therapies used for clear cell mRCC and consisted of tyrosine kinase inhibitors, mechanistic target of rapamycin inhibitors and recently checkpoint inhibitors. Median progression‐free survival from start of first‐line treatment was 5.4 months (95% confidence interval [CI], 4.1–9.2) and median overall survival was 12.0 months (95% CI, 8.1–20.0). At data cutoff, 73% of the patients died, 6% were still observed, 12% were lost to follow‐up, and 9% were alive at the end of the individual 3‐year observation period. Despite the lack of prospective Phase III evidence in patients with papillary mRCC, our real‐world data reveal effectiveness of systemic clear cell mRCC therapy in papillary mRCC. The prognosis seems to be inferior for papillary compared to clear cell mRCC. Further studies are needed to identify drivers of effectiveness of systemic therapy for papillary mRCC.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

“…Further details on the methodology of the RCC-Registry have been previously described elsewhere. 18,19…”

Section: Data Sourcementioning

confidence: 99%

See 3 more Smart Citations

Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC‐Registry

Staehler

Goebell

Müller³

et al. 2019

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

Was machen Urologen in der Praxis?

Goebell

El-Khadra²,

Horstmann

et al. 2021

Urologe

Self Cite

View full text Add to dashboard Cite

ZusammenfassungAuch (berufs)politisch hat das Thema Versorgung und Versorgungsforschung an Relevanz gewonnen und stellt für die Gesundheitspolitik und die an der Versorgung Beteiligten eine wichtige Basis dar. Der Zugang zu relevanten Daten und die Möglichkeiten zur Analyse sind daher umkämpfter denn je, liefern sie doch die besten Argumente und Fakten in jedem Diskurs um letztlich begrenzte Ressourcen des gesamten Gesundheitssektors. Allen randomisierten klinischen Studien und prospektiven Datensammlungen ist gemein, dass sie einen festen vordefinierten Rahmen der zu erfassenden verschiedenen Datenpunkte zugrunde gelegt haben, um störende Einflussfaktoren möglichst zu kontrollieren. Auch Analysen aus retrospektiven Datensammlungen benutzen eine vordefinierte Auswertematrix und filtern die vorhandenen Daten auf diese festgelegten Datenpunkte. Ein ungefilterter Blick auf alle Daten wäre aber der Idealzustand. Näherungsweise sollten in diesem Projekt so viele Daten wir möglich „ungefiltert“ erfasst werden und in einem Datenpool gesammelt werden, die dann durch sich ständig verbessernde Analysealgorithmen aufgearbeitet werden können. Über die automatisierte Extraktion von Daten aus dem Arzt‑/Praxisinformationssystem (AIS) in UROscience wird ein Datenpool entstehen, der für viele Fragestellungen zur Versorgungsrealität genutzt werden kann. Die hier vorgestellte erste Analyse zeigt, dass auf Basis der bereits vorhandenen Daten eine vielseitig einsetzbare Stichprobe für die Darstellung des Versorgungsalltags aus der urologischen Praxis zur Verfügung steht.

show abstract

Importance of phase enhancement for machine learning classification of solid renal masses using texture analysis features at multi-phasic CT

et al. 2020

View full text Add to dashboard Cite

Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma – Analyses From the German Clinical RCC-Registry

Cited by 22 publications

References 55 publications

Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC‐Registry

Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC‐Registry

Was machen Urologen in der Praxis?

Importance of phase enhancement for machine learning classification of solid renal masses using texture analysis features at multi-phasic CT

Contact Info

Product

Resources

About